8-K: Neuphoria Therapeutics Receives Nasdaq Deficiency Notice for Missed Annual Meeting

Neuphoria Therapeutics Inc. has received a deficiency notification from Nasdaq for failing to hold its annual stockholder meeting within the required timeframe, though the company states it has a plan to regain compliance.

Summary

• Neuphoria Therapeutics Inc. received a deficiency notification from The Nasdaq Stock Market LLC on July 18, 2025.
• The notice indicated non-compliance with Nasdaq Listing Rule 5620(a) due to the company's failure to hold an annual meeting of stockholders within twelve months of its fiscal year ended June 30, 2024.
• The company has until September 1, 2025, to submit a plan to regain compliance with the Listing Rule.
• If Nasdaq accepts the plan, the company may be granted an exception of up to 180 calendar days from the end of its fiscal year, or until December 29, 2025, to regain compliance.
• The deficiency notice has no immediate effect on the listing of the company's common stock on Nasdaq.

Sentiment

Score: 4

Explanation: The company received a deficiency notice from Nasdaq, which is a negative event. However, the notice has no immediate effect on listing, and the company has a clear plan and timeline to regain compliance, mitigating some of the negative impact.

Positives

• The deficiency notice has no immediate effect on the listing of the company's common stock on Nasdaq.
• The company has a stated plan to regain compliance, including holding its 2025 annual general shareholder meeting around November 2025, consistent with past practices.
• The company intends to submit its compliance plan by September 1, 2025.
• The company plans to timely file its annual report on or before September 30, 2025.

Negatives

• Neuphoria Therapeutics Inc. received a deficiency notification from Nasdaq for non-compliance with Listing Rule 5620(a).
• The company failed to hold its annual meeting of stockholders within twelve months of the fiscal year ended June 30, 2024.

Risks

• The ability of the company to maintain the listing of its securities on Nasdaq.
• General risks and uncertainties that could cause actual results to differ from forward-looking statements.

Future Outlook

The company plans to submit a compliance plan to Nasdaq by September 1, 2025, and intends to hold its 2025 annual general shareholder meeting around November 2025 to satisfy the listing rule. It also expects to file its annual report by September 30, 2025.

Management Comments

• "The Company notes that it has held a shareholder meeting every year for the past number of years on or about November or December of each such year, including the extensive shareholder meeting we held in relation to our redomicilation and scheme of arrangement to become a Delaware corporation in December 2024."
• "To this end, the Company had already planned to hold its 2025 annual general shareholder meeting on or about November 2025, in-line with past annual shareholder meeting dates, in satisfaction of the compliance item provided in the Notice and which will be consistent with the Plan that the Company intends to submit on a timely basis."
• "The Company also looks forward to timely filing its annual report on or before September 30, 2025, as well as its upcoming annual shareholder meeting communication(s) shortly thereafter."

Industry Context

This announcement primarily concerns a corporate governance and listing compliance issue specific to Neuphoria Therapeutics Inc. and does not directly reflect broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector. It highlights the ongoing regulatory scrutiny faced by publicly traded companies regarding adherence to listing standards.

Comparison to Industry Standards

• Nasdaq Listing Rule 5620(a) requires all Nasdaq-listed companies, including those in the biotechnology sector, to hold an annual meeting of shareholders no later than one year after the end of their fiscal year. Neuphoria Therapeutics Inc.'s failure to meet this standard for its fiscal year ended June 30, 2024, places it out of compliance with a fundamental corporate governance requirement common across all public companies.
• While the company states it held an "extensive shareholder meeting" in December 2024 related to redomiciliation, this meeting did not fulfill the requirement for the annual meeting for the fiscal year ended June 30, 2024, indicating a potential misinterpretation or oversight of specific regulatory requirements compared to standard industry practices for annual general meetings.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential risk to the continued listing of common stock on Nasdaq if compliance is not regained, though there is no immediate effect. The company's plan to regain compliance aims to protect shareholder interests by maintaining listing.
• Regulatory Authorities: The company is under scrutiny from Nasdaq for non-compliance with listing rules, requiring a formal response and action plan.

Next Steps

• Submit a plan to Nasdaq to regain compliance by September 1, 2025.
• Hold the 2025 annual general shareholder meeting around November 2025.
• Timely file the annual report on or before September 30, 2025.
• Issue upcoming annual shareholder meeting communication(s) shortly after the annual report filing.

Key Dates

Recommendation

Keywords

Neuphoria Therapeutics, Nasdaq, Listing Rule 5620(a), Annual Meeting, Deficiency Notice, Compliance, Corporate Governance, SEC Filing, 8-K